Starpharma ROCE
Was ist das ROCE von Starpharma?
ROCE von Starpharma Holdings Limited ist 0.00%
Was ist die Definition von ROCE?
Die Kapitalerträge (ROCE) entsprechen einer Finanzkennzahl, die die Rentabilität eines Unternehmens und die Effizienz, mit der sein Kapital verwendet wird, misst.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE von Unternehmen in Health Care Sektor auf ASX im Vergleich zu Starpharma
Was macht Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Unternehmen mit roce ähnlich Starpharma
- Omega Alpha Spac hat ROCE von -0.01%
- The Gap hat ROCE von -0.01%
- Elemental Royalties Ltd hat ROCE von -0.01%
- Auburn National Bancorp hat ROCE von -0.01%
- Galaxy Digital hat ROCE von -0.01%
- The Gap hat ROCE von -0.01%
- Starpharma hat ROCE von 0.00%
- Tejon Ranch Co hat ROCE von 0.01%
- Glen Burnie Bancorp hat ROCE von 0.02%
- MSP Steel & Power hat ROCE von 0.02%
- TTL Beteiligungs- und Grundbesitz-AG hat ROCE von 0.03%
- First Foundation Inc hat ROCE von 0.03%
- FirstMark Horizon Acquisition hat ROCE von 0.03%